What the Expanding Reach of Weight-Loss Drugs Means For Health Care 10/11/23
Shares of medical device makers like Davita and Baxter International plunged after Novo Nordisk said its GLP-1 drug Ozempic had some positive results in trials against kidney failure. So what could the impact be of a potential do-it-all drug? We surround the trade with Dr. Kavita Patel and Mizuho’s Jared Holz. Fast…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from CNBC's "Fast Money"
See all episodes →Record national debt as stocks keep climbing…and retail investor playbook 8/13/26
AI stocks back in the spotlight... And a bold call for three rate hikes this year 8/12/26
“Big Short” investor’s AI warning... And a key inflation report on deck 8/11/26
Similar episodes from other shows
More like CNBC's "Fast Money" →
Here's How the New Weight Loss Drugs Could Change Everything
The State of Weight-Loss Drugs
Can a GLP-1 Pill Revive Novo Nordisk?
How Ozempic Transformed the Way We Look at Obesity
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.